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ABSTRACT 
Objective: To determine whether dihydroartemisinin-piperaquine (DHA-PPQ) is non-inferior to ar-
tesunate-amodiaquine (ASAQ) for treating uncomplicated malaria infection in pregnancy. 
Methods: 417 second/ third trimester pregnant women with confirmed asymptomatic Plasmodium 
falciparum parasitaemia were randomized to receive DHA-PPQ or ASAQ over 3 days. Women were 
followed up on days 1, 2, 3, 7, 14, 28 and 42 after treatment start and at delivery for parasitological, 
haematological, birth outcomes and at 6-weeks post-partum to ascertain the health status of the 
babies. Parasitological efficacy (PE) by days 28 and 42 were co-primary outcomes. Analysis was per-
protocol (PP) and modified intention-to-treat (ITT). Non-inferiority was declared if the two-sided 
95% confidence interval for PE at the endpoints excluded 5% lower efficacy for DHA-PPQ. Secondary 
outcomes were assessed for superiority. 
Results: In PP analysis, PE was 91.6% for DHA-PPQ and 89.3% for ASAQ by day 28 and 89.0% and 
86.5% respectively by day 42. DHA-PPQ was non-inferior to ASAQ with respect to uncorrected PE 
{adjusted difference by day 28 (DHA-PPQ-ASAQ); 3.5% (95%CI: -1.5, 8.5) and day 42: 3.9% (95%CI: -
2.7, 10.4)}. ITT analysis gave similar results. PCR to distinguish recrudescence and reinfection was 
unsuccessful. DHA-PPQ recipients had fewer adverse events of vomiting, dizziness and general 
weakness compared to ASAQ. Both drugs were well-tolerated and there was no excess of adverse 
birth outcomes.  
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Conclusion: DHA-PPQ was non-inferior to ASAQ for treatment of malaria infection during pregnancy. 
No safety concerns were identified. Our findings contribute to growing evidence that DHA-PPQ is 
useful for control of malaria in pregnancy. 
 
keywords: Dihydroartemisinin-piperaquine, artesunate-amodiaquine, malaria in pregnancy, treat-
ment, safety, efficacy, tolerability, non-inferiority trial, Ghana 
 
INTRODUCTION 
Pregnancy-associated malaria remains a challenge in endemic countries. Plasmodium falciparum 
infections in this population, symptomatic or not, carry an important burden of maternal anaemia 
and death, pregnancy wastage, preterm delivery and low birth weight (LBW) with increased risk of 
infant deaths [1-6]. Measures to mitigate these adverse outcomes include sleeping under long-
lasting insecticide nets (LLINs), intermittent preventive treatment with sulphadoxine-pyrimethamine 
(IPTp-SP) and prompt diagnosis and treatment using artemisinin-based combination therapies (ACTs) 
[7]. Screening pregnant women intermittently with malaria rapid diagnostic tests (mRDT) and treat-
ing positives using ACTs (intermittent screening and treatment, ISTp) has also been studied and 
showed variable outcomes compared to IPTp-SP [8, 9]. The ISTp approach was suggested to coun-
teract reported declining SP efficacy [10] but the WHO has reiterated the use of SP for IPTp [11]. 
 Dihydroartemisinin-piperaquine (DHA-PPQ) and artemether-lumefantrine (AL) were officially 
adopted in Ghana in 2010 as first-line alternatives to ASAQ for malaria case management. At the 
time of planning the study, no specific guidelines existed in relation to the use of DHA-PPQ in preg-
nancy due to few data on safety and efficacy in this population.   Studies, including a systematic re-
view, have however reported good safety and efficacy for DHA-PPQ used as treatment and preven-
tion in children and non-pregnant adults [12-15]. In a recent systematic review including pregnant 
participants, IPT using DHA-PPQ was associated with 84% reduction in the incidence of malaria para-
sitaemia compared to placebo [16]. 
 Early reports of DHA-PPQ treatment of PAM showed a day 63 PCR-corrected efficacy of 92.2% in 
Western Cambodia [17] and lower risks of perinatal death and parasitaemia at delivery in women 
receiving DHA-PPQ compared to women receiving quinine, chloroquine, or SP in Papua New Guinea 
[18]. However these trials were not randomized. A multi-country trial of four ACTs for treating ma-
laria in pregnancy (including DHA-PPQ, ASAQ, AL and artesunate-mefloquine) in Ghana, Burkina 
Faso, Malawi and Zambia reported a day 63 PCR-adjusted cure rate of 99.2% for DHA-PPQ [19].  
 The objectives of the current study were to assess the efficacy, safety and tolerability of DHA-
PPQ for treatment of asymptomatic P.falciparum infection in the second and third trimesters as data 
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in pregnancy is limited. Understanding how well DHA-PPQ clears existing infections is important 
when considering this drug as an alternative treatment for malaria in pregnancy and perhaps its 
potential for IPTp indirectly. The control was ASAQ which is standard in Ghana and has high efficacy 
with PCR-adjusted cure rates of ≥95% in pregnant women [19, 20]. The study design was, therefore, 
a randomized non-inferiority trial of DHA-PPQ with the co-primary outcomes being parasitological 
efficacy at days 28 and 42 after starting treatment. In consideration of the potential advantages of 
DHA-PPQ over ASAQ, including better tolerability, once daily dosing (ASAQ is given in two divided 
doses in Ghana) and the longer terminal half-life of piperaquine compared to amodiaquine [13, 21], 
a margin of 5% lower efficacy in DHA-PPQ was considered clinically relevant. 
 
METHODS 
Study design 
This was an open-label, individually-randomized (1:1), non-inferiority trial with two arms.  
 
Study area and population 
The study was conducted from July 2011 to October 2012 in the Bosomtwe and Bekwai areas in the 
middle forest belt of Ghana, where malaria transmission is moderate to high year round with peaks 
in the rainy season (March-July and September-November). P.falciparum accounts for ≥90% of all 
malaria, and infection prevalence was up to 50% among children ˂5 in Bosomtwe district in 2012 
[22]. The study population comprised pregnant women of gestational age 15-32 weeks accessing 
antenatal care (ANC) at St. Michael’s Hospital in the Bosomtwe district and the Bekwai Government 
Hospital. Gestational age and foetal viability at recruitment were determined using ultrasound scan. 
 
Sample Size 
A day-28 PCR-corrected parasite clearance of 95.5% was assumed for ASAQ treatment in pregnant 
women based on a study in Tanzania [21]. At 90% power and a two-sided 5% significance level, 361 
pregnant women per study arm would be needed to demonstrate noninferiority of DHA-PPQ to 
ASAQ. Allowing for a 20% loss to follow up, the sample size was estimated at 452 in each study arm 
[23].   
 
Participant selection and study procedures 
Detailed selection and study procedures are provided in the supplementary appendix. Women were 
only eligible if they had P.falciparum parasitaemia by both RDT (First Response®, Premier Medical 
Corporation, India) and microscopy. Exclusion criteria included multiple gestation, positive HIV 
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status, severe renal/cardiac disease or Hb<7.0g/dl. Women were randomized to receive either a co-
blistered preparation of ASAQ or co-formulated DHA-PPQ over 3 days. According to standard guide-
lines, participants received IPTp-SP at study completion if there was at least a month left to term or 
if they were withdrawn from the study. All women received LLINs, daily iron and folic acid supple-
mentation according to national policy. 
 Follow-ups were conducted on days 1, 2, 3, 7, 14, 28 and 42 after treatment start for assess-
ment of adherence to treatment and occurrence of adverse and severe adverse events (AEs and 
SAEs) and blood sampling for haematology, microscopy and filter spot preparation. Women with 
recurrent infections at days 7, 14, 28 and 42 or any day between days 3 and 42 for unscheduled vis-
its were given Quinine tablets at a dose of 10mg/Kg three times daily for seven days. Assessments 
were conducted at delivery and 6 weeks post-partum for perinatal outcomes including birth weight, 
stillbirths, congenital abnormalities and neonatal morbidity and mortality.  
 For maternal peripheral blood sampling, study workers collected 5ml of venous blood into EDTA 
tubes labelled with the sampling date, participant’s identity number and follow-up day. Labour ward 
midwives were trained to cut 1cm x 1cm placental blocks from the maternal surface close to the 
insertion of the cord for preparation of placental smears. They were also trained to draw blood from 
the umbilical vein from the placental stump of the cord after baby had been separated from the 
cord. Haematological parameters were analysed using an autoanalyzer (Sysmex KX-21N, Sysmex 
Corp, Japan).   Dried blood spots prepared using Whatmann 1MM filter papers (Whatmann, Maid-
stone, England) were stored in individual zip-lock bags with silica gel. Thick and thin blood films were 
prepared for microscopy. A laboratory technologist read all blood films and quantified parasitaemia 
against 200 white blood cells, assuming a WBC count of 8,000/µl of blood. A thick blood film was 
declared negative only after 100 high power fields had been examined. A second microscopist read 
15% of all slides. Agreement with the study microscopist was 89% with a kappa statistic of 0.6 sug-
gesting moderate agreement. Discrepancies were settled by taking the results from the second mi-
croscopist. 
 Parasite DNA was extracted using the Chelex method with some modifications [24, 25] and used 
for PCR genotyping to differentiate reinfection from recrudescence using procedures described ear-
lier [26].  
 
Data Management and Statistical Methods 
Data were double-entered and analysed using Stata 12 (Stata Corp, College Station, Texas, USA) af-
ter consistency checks. Parasitological efficacy by day 28 and 42 was defined as absence of parasi-
taemia and without prior rescue medication at any point. Secondary outcomes included changes in 
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maternal Hb, total white blood cell, differential and platelet counts at days 14, 28 and 42 over base-
line, proportions of AEs and SAEs, birth weight, proportions of adverse pregnancy outcomes (spon-
taneous abortions, preterm deliveries, stillbirths and neonatal mortalities) and proportions of ma-
ternal peripheral, placental and cord blood parasitaemia. 
 Per protocol and “modified intention-to-treat” analyses of the primary outcome were under-
taken. The per protocol population comprised women who took ≥ 2 days course of assigned treat-
ments, had ≥ 4 follow-up visits with no major protocol violation with a parasitological outcome at 
days 28 and 42 days. The “modified intention-to-treat” group included all randomized women who 
took the first dose of treatment with a parasitological outcome.  
 For analysis of the co-primary outcomes, treatment differences between study arms (adjusted 
and unadjusted) and the two-sided 95% confidence intervals around them were calculated using 
binomial regression with identity link. Non-inferiority was inferred when the lower limit of the confi-
dence interval was above the pre-defined margin of -5%.  
 
Ethics 
The Committee on Human Research and Publication Ethics (CHRPE) of the Kwame Nkrumah Univer-
sity of Science and Technology, Kumasi, Ghana approved the study protocol. A data safety and moni-
toring board (DSMB) monitored the study. The study was registered with ClinicalTrials.gov 
(NCT01231113). 
 
RESULTS 
A total of 3464 women in second and third trimester were screened for peripheral P.falciparum 
parasitaemia between July 2011 and October 2012 using mRDT and microscopy. Of these, 588 (17%) 
were mRDT positive. As shown in the trial profile (Figure 1), 171 were excluded and the remaining 
417 women were recruited. Of the participants, 91.6% (382/417) were followed up on day 28 and 
89.0% (371/417) on day 42. Only 56.8% (237/417) and 42.2% (176/417) were available for assess-
ments at delivery and at 6 week post-partum respectively.  
 Background characteristics of participants were comparable between the two arms and are 
shown in Table 1. Nulliparous and primiparous women comprised over 50% (221/416). About 60% 
(239/403) reported owning treated nets but only 40% (137/340) slept under them the night before 
the survey. Close to two-thirds (252/386) of the women were anaemic (Hb ˂ 11g/dl). The DHA-PPQ 
arm had more women within the lowest Hb category (14.5% vs 7.8%; p=0.04). Baseline parasite den-
sity was ˂500/µl in 84.4% (342/405) of the women. 
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Parasitological efficacy of DHA-PPQ versus ASAQ 
Differentiation of recrudescent from new infections by PCR genotyping was not considered reliable 
as the process yielded very few positives at the defined end points. This was most likely due to poor 
sensitivity at low parasite densities. Consequently, only PCR-uncorrected estimates of parasitological 
efficacy are reported. In the per-protocol analysis, parasitological efficacy by day 28 was 91.6% 
(95%CI: 86.7, 95.1) in the DHA-PPQ arm and 89.3% (95%CI: 83.8, 93.5) in the ASAQ arm and 89.0% 
(95%CI: 83.6, 93.0) and 86.5% (95%CI: 80.6, 91.2%) by day 42 (Table 2). The lower boundaries of the 
95% confidence interval around the difference excludes the pre-specified non-inferiority margin of 
minus 5%. Unadjusted differences (DHA-PPQ efficacy-ASAQ efficacy) were 2.3 (95%CI: -3.8, 8.3) and 
2.5 (95%CI: -4.3, 9.1) by days 28 and 42 respectively. Similarly, adjusted differences were 3.5 (95%CI: 
-1.5, 8.5) and 3.9 (95%CI: -2.7, 10.4) respectively. 
 Similar results were observed in the modified intention-to-treat population except for the day 
42 crude risk difference where non-inferiority could not be excluded as the lower boundary of the 2-
sided 95% confidence interval overlapped the minus 5% non-inferiority margin (Table 2). None of 
the baseline variables; age, gestational age, gravidity, parasite density and Hb concentration was 
associated with parasitological outcome by days 28 and 42 (data not shown). 
 
Secondary outcomes 
Between treatment start and day 28, the ASAQ group showed an increase of 0.7g/dl (10.1 g/dl vs. 
10.8g.dl; p˂0.0001) in Hb while the DHA-PPQ arm had an increase of 0.6g/dl (10.0g/dl vs. 10.6g/dl; 
p=0.0001). Similar increases were observed between day 0 and day 42; (10.1g/dl vs. 11.2g/dl; 
p<0.0001) for ASAQ and (10.0g/dl vs. 10.8g/dl; p<0.001) for DHA-PPQ groups. There was no differ-
ence in mean Hb between study arms at day 28 (10.8g/dl in ASAQ arm vs. 10.6 g/dl in DHA-PPQ arm; 
p=0.25) (Table 1 in supplementary appendix). The ASAQ group, however, had a higher mean Hb at 
day 42 (11.2g/dl vs. 10.8g/dl; p=0.01). Neutrophil and lymphocyte counts showed significant varia-
tion over baseline at days 14, 28 and 42 in each arm (Tables 2 and 3 in supplementary appendix). 
There were however no differences between study arms regarding differential and platelet counts 
(Table 1 in supplementary appendix). 
 There were no differences in mean maternal Hb levels at delivery (Table 3). Birth weight records 
were obtained for less than half (162/417) of study women. Mean birth weight was 2.95Kg (95%CI: 
2.86, 3.04) in the ASAQ arm and 2.94 kg (95%CI: 2.82, 3.06) in the DHA-PPQ arm. Overall, LBW was 
observed in 9.3% (15/162) of babies and was higher in the DHA-PPQ arm [13.2% (12/91) vs. 4.2% 
(3/72); p=0.05]. A significantly lower prevalence of peripheral parasitaemia was observed in the 
DHA-PPQ group at delivery (37.1% vs. 21.7%; p=0.01) but there were no differences in the preva-
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lence of cord and placental parasitaemia.  
 Generally, the drugs were well tolerated. Adverse events were mild and included general weak-
ness, vomiting, nausea, dizziness, abdominal pains and anorexia. These peaked on day 3 (Table 4) 
but were mostly resolved by day 7 (Table 5). Women in the ASAQ arm reported more AEs; anorexia 
(12.0% vs. 22.3%; p=0.007), vomiting (19.5% vs. 29.4%; p=0.02), dizziness (14.5% vs. 26.6%; p=0.003) 
and general weakness (38.5% vs. 62.5%; p<0.0001). Adverse events were recorded on day 14 but 
there were no differences between study arms (Table 4 in supplementary appendix). Adverse events 
reported were similar to self-reported complaints present within the month preceding enrolment 
(Table 5 in supplementary appendix).  
 No maternal mortality was recorded. There were eight cases of SAEs due to hospitalizations; 4 in 
each arm. The DHA-PPQ arm recorded a case each of severe anaemia (Hb 3.8g/dl), pregnancy in-
duced hypertension (PIH), antepartum haemorrhage (placenta abruptio) and severe diarrhoea. In 
the ASAQ arm, there were three cases of severe diarrhoea and a suspected appendicitis. Further-
more, two cases each of neonatal deaths and stillbirths were recorded in the DHA-PPQ arm while 
one case of stillbirth was observed in the ASAQ arm. Three cases of polydactyly and a case of gum 
swelling were observed in the DHA-PPQ arm but no congenital anomaly was recorded for the ASAQ 
arm. 
 
DISCUSSION 
The study found that DHA-PPQ was non-inferior to ASAQ with respect to uncorrected parasitological 
efficacy and appeared to be better tolerated. No safety concerns were identified. These findings 
concur with previous studies where DHA-PPQ was found non-inferior to other ACTs such as artesu-
nate-mefloquine and artemether-lumefantrine and reported to be comparable to ASAQ [19, 27-29].  
 The day 42 PCR-uncorrected and unadjusted efficacy of ASAQ was slightly less than 90% in both 
per protocol and modified intention-to-treat populations and is comparable to PCR-uncorrected cure 
rates observed in the PREGACT study which reported a day 63 PCR-uncorrected cure rate of 82.3% 
but a corrected cure rate over 95% [19]. Similarly, the day 28 uncorrected unadjusted efficacy for 
ASAQ in the PP population compares favourably with the PCR-uncorrected estimate for the same 
time point in Tanzanian pregnant women [20]. The day 42 PCR-uncorrected unadjusted DHA-PPQ 
efficacy in the PP is also comparable to the uncorrected estimates for day 63 in Ghana, Malawi and 
Zambia in the PREGACT study [19]. If PCR genotyping had been successful, much higher efficacy es-
timates may have been observed as majority of day 42 positives would likely have been new infec-
tions and the two antimalarials may have been good alternatives in terms of efficacy. The finding of 
DHA-PPQ non-inferiority to ASAQ should be interpreted with caution in light of some study limita-
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tions discussed below.  
 Less than half of the estimated sample size was recruited; largely because of a lower-than-
expected prevalence of parasitaemia among ANC attendants. This may be related to a nationwide 
distribution of LLINs at the initial stages of the study although only 40% of women reported sleeping 
under them the night before enrolment. Furthermore, there was a period of 3 months when no 
women were recruited due to protests against health finance reforms piloted in the Ashanti region 
at the time. Coupled with loss to follow up, there were implications for reduced study power, dimin-
ished treatment differences and a bias towards non-inferiority. However, with the sample size 
achieved, our study indicates that efficacy of DHA-PPQ is comparable to that of ASAQ, excluding an 
important difference and the point estimate was in favour of DHA-PPQ. This is consistent with other 
studies [17, 19] indicating the combination has high efficacy at clearing malaria infection. The longer 
period of post-treatment prophylaxis for DHA-PPQ compared to ASAQ (by extension, more reinfec-
tions in ASAQ) may explain why the uncorrected efficacy was slightly higher. Losses to follow-up for 
birth outcomes were high but those who were followed until delivery were comparable to those 
enrolled at baseline and there were no systematic differences in those followed until delivery be-
tween study arms (see supplementary appendix). 
 The longer period of post-treatment prophylaxis for DHA-PPQ compared to ASAQ (by extension, 
more reinfections in ASAQ) may explain why the uncorrected efficacy was slightly higher. It is possi-
ble treatment efficacy may be more similar if reinfections had been corrected for. Based on its high 
efficacy at clearing malaria infection and longer post-treatment prophylaxis, DHA-PPQ has potential 
for use as IPTp. Recent studies in East Africa showed IPTp-DHA-PPQ had lower prevalence of his-
tologically confirmed placental malaria, parasitaemia at delivery and incidence of malaria compared 
to IPTp-SP [9, 30]. 
 It is unclear why PCR-genotyping to differentiate recrudescent from new infections was unsuc-
cessful and may have arisen from a number of causes. Silica gels in individual zip-lock bags probably 
should have been changed more often than was done considering the relatively long storage dura-
tion of some of the filter papers (≥10 months) at possibly high temperatures/ humidity until actual 
DNA extraction for analysis at the msp1, msp2 and glurp genes. These may have contributed to DNA 
degradation and obstructed the expected high sensitivity of the standard PCR and subsequently 
reduced PCR sensitivity. Nonetheless, every P.falciparum infection in pregnant women may have 
important consequences for the health of baby and mother and the PCR-uncorrected estimates re-
ported still hold relevance. 
 The relatively low agreement of 89% between the microscopy readers is acknowledged as a 
limitation. The standard is to have each slide double-read with a third read where there are dis-
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agreements. However, the impact thereof is mitigated by roughly even distribution of false positive 
and false negative slides (52% vs 48%) such that the effects of a misclassification bias was minimized. 
 The occurrence of a higher mean Hb at day 42 in the ASAQ arm compared to the DHA-PPQ arm 
contrasts with reports of better haematological recovery associated with DHA-PPQ [13, 22, 31]. This 
may be a chance finding and may be a follow-on from the lower Hb in more women at baseline in 
the DHA-PPQ group despite the integrity of the randomization process. Contrary to reports of de-
creased white blood cell counts with DHA-PPQ [32, 33], the present study did not observe this. Re-
duced neutrophil counts over baseline (Table 1 in supplementary appendix) may be adverse events 
associated with artemisinin derivatives [34] while the observed increased lymphocyte count is con-
sistent with pregnancy itself [35]. It is possible that the lack of differences between study arms may 
be due to inadequate power on account of the low numbers assessed for some of the haematologi-
cal indicators. 
 The higher prevalence of LBW in the DHA-PPQ arm is thought to be a chance finding and not 
attributable to DHA-PPQ. Available evidence from studies using DHA-PPQ for treatment or preven-
tion of malaria in pregnancy [17, 19, 9, 30] do not suggest an association between DHA-PPQ use and 
excess of LBW. Nutritional status was not assessed but the women had similar background charac-
teristics. The common AEs observed were comparable to those reported for both study drugs in 
previous studies and were fewer in the DHA-PPQ arm [12, 16, 19, 30]. No participant left the study 
or stopped the treatment on account of adverse events, suggesting good tolerability of both drugs 
especially DHA-PPQ on account of better side-effect profile. Adverse events reported at day 14 were 
deemed to be more likely pregnancy-related than a result of study treatment. 
 There was no excess of SAEs in the DHA-PPQ arm and only severe diarrhoea was thought to be 
plausibly linked to the study treatments, especially ASAQ [36, 37], in terms of time between expo-
sure and occurrence. The case of placental abruption, though occurring within 3 days after start of 
treatment, is not likely to be attributable to DHA-PPQ as there is no known plausible mechanism by 
which DHA-PPQ may cause it. The occurrence of polydactyly in the DHA-PPQ arm is similar to that 
reported among Ghanaian pregnant women who received AQ for treatment [38]. It is deemed to be 
within background occurrence and not related to DHA-PPQ.  A pilot study of DHA-PPQ in pregnant 
women [17] reported one case each of Patau’s syndrome (trisomy 13) and umbilical hernia but not 
polydactyly. Congenital malformations were reported for all four ACTs including DHA-PPQ with a 
prevalence range of 0.8%-2.0% in the PREGACT Study [19]. 
 Similarly, the other SAEs observed were not considered to be major deviations from background 
occurrences of pregnancy complications. In the first quarter of 2014, 3 cases of antepartum haemor-
rhage and 18 cases of hypertensive diseases in pregnancy were managed at St. Michael’s hospital 
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(unpublished data).  
 
Conclusion 
The results of this study add to a growing evidence base that DHA-PPQ is effective and safe for 
treatment of malaria in pregnancy. The better tolerability and single daily dosage regimen for DHA-
PPQ is expected to augur well for better adherence. Future research is needed regarding long term 
effects on developmental milestones in babies born to mothers who received DHA-PPQ treatment 
and to evaluate rarer adverse events including possible LBW. Furthermore, if DHA-PPQ were to be 
considered for IPTp, more data on effectiveness of the 3-day regimen under routine operational 
conditions as well as acceptability studies would be required. 
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Table 1: Baseline demographic and clinical characteristics of study women 
variable ASAQ (%) 
(N=205) 
DHA-PPQ (%) 
(N=212) 
p-value Total (%) 
 
Education (n=415) 
   
0.91 
 
None 24 (11.8) 20 (9.5)    44 (10.6) 
Primary 29 (14.2) 32 (15.2)    61 (14.7) 
aJunior High School 129 (63.2) 135 (64.0)  264 (63.6) 
bSenior High School 19 (9.3) 19 (9.0)    38 (9.2) 
Tertiary 3 (1.5) 5 (2.4)     8 (1.9) 
     
Age  (n=417)   0.05  
15-19 40 (19.5) 29 (13.7)    69 (16.5) 
20-24 56 (27.3) 77 (36.3)  133 (31.9) 
25-29 56 (27.3) 67 (31.6)  123 (29.5) 
≥30 53 (25.9) 39 (18.4))    92 (22.1) 
     
Gestational Age 
(n=405) 
  0.61  
<24 weeks 111 (56.4) 112 (53.9)  223 (55.1) 
≥24 weeks 86 (43.7) 96 (46.2)  182 (44.9) 
Mean gestational age 22.3(95%CI; 21.6, 22.9) 22.7(95%CI; 22.1, 
23.4) 
0.33  
     
Parity (n=416)   0.12  
Nulliparous 54 (26.3) 74 (35.1)  128 (30.8) 
Primiparous 46 (22.4) 47 (22.1)    93 (22.3) 
Multiparous 105 (51.2) 90 (42.7)  195 (46.9) 
     
ITN Ownership 
(n=403) 
  0.84  
Yes 117 (58.8) 122 (59.8)  239 (59.3) 
No 82 (41.2) 82 (40.2)  164 (40.7) 
     
Slept in ITN last night 
 (n=340) 
  0.19  
Yes 61 (36.8) 76 (43.7)  137 (40.3) 
No 105 (63.3) 98 (56.3)  203 (59.7) 
 
Parasite Density 
(n=405) 
   
0.99 
 
<500/µl 169 (84.5) 173 (84.5)  342 (84.4) 
≥500/µl 31 (15.5) 32 (15.5)  63 (15.6) 
Geometric Mean 
Parasite Density 
238 (95%CI;199, 285) 236 (95%CI; 193, 289) 0.28  
     
c
Hb (n=386)   0.04  
7-8.9 15 (7.8) 28 (14.5)  43 (11.1) 
9-10.9 115 (59.6) 94 (48.7)  209 (54.1) 
≥11 63 (32.6) 71 (36.8)  134 (34.7) 
Mean Haemoglobin  10.1 (95%CI; 9.9, 10.2) 10.0 (95%CI; 9.8, 10.2) 0.44  
a Junior High School refers to 3 years while bSenior High School refers to 6 years of secondary school education post primary school. 
cHaemoglobin  in g/dl.  
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Table 2: Parasitological efficacy by study arms in the two analyses populations 
PER PROTOCOL POPULATION 
 Treatment group 
 
Crude dif-
ference  
 
95% CI Adjusted 
difference 
95% CI 
 ASAQ efficacy DHA-PPQ efficacy     
 N           n         % N           n         %     
Day 28 178       159     89.3 190       174     91.6 2.3 (-3.8, 8.3) 3.5 (-1.5, 8.5) 
       
Day 42 178        154     86.5 190       169      89.0 2.5 (-4.3, 9.1) 3.9 (-2.7, 10.4) 
       
MODIFIED INTENTION-TO-TREAT POPULATION 
 
 
 
 Treatment group 
 
Crude dif-
ference  
 
95% CI Adjusted 
difference 
95% CI 
 ASAQ efficacy DHA-PPQ efficacy     
 N           n         % N           n         %     
Day 28 184       164     89.1 199       180     90.4 1.3 (-4.8, 7.4) 3.3 (-2.3, 8.9) 
       
Day 42 180        156     86.7 191       167      87.4 0.7 (-6.1, 7.6) 2.1 (-2.7, 8.9) 
N is total number assessed at end point. n is number without malaria infection and % represents efficacy. ‘Adjusted’ refers to 
differences in parasitological efficacy controlling for age, gestational age, Hb, gravidity and parasite density at enrolment. 
Differences are obtained as efficacy in DHA-PPQ group minus efficacy in ASAQ group. 
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Table 3: Comparison of delivery and 6-week post-partum assessments between study 
arms 
 
 
 
 
ASAQ 
 
 
DHA-PPQ p-value 
    
Maternal Hb at delivery 
{
*
N, mean (95%)} 
74,12.0 (11.5, 12.4) 87,11.5 (11.2, 11.9) 0.10 
    
&
Peri. parasitaemia (N)   97 120 0.012 
Yes 36 (37.1%) 26 (21.7%)  
No 61 (62.9%) 94 (78.3%)  
    
$
Plac. parasitaemia(N) 90 116 0.43 
Yes 19 (21.1%) 30 (25.9%)  
No 71 (78.9%) 86 (74.1%)  
    
Cord parasitaemia(N) 85 105 0.90 
Yes 26 (30.6%) 33 (31.4%)  
No 59 (69.4%) 72 (68.6%)  
    
Gestation (N) 96 122 0.92 
≥37 weeks n (%) 91 (94.8%) 116 (95.1%)  
<37 weeks n (%) 5 (5.2%) 6 (4.9%)  
    
Congenital abnormality 0 4 (3 cases of polydactyly 
and 1 case of gum swell-
ing) 
 
    
Stillbirths 1 2  
    
Miscarriage 1 1  
    
Intrauterine death 1 0  
    
Neonatal deaths 0 2  
    
Neonatal Jaundice 2 2  
*N is number assessed for outcome &Peripheral parasitaemia    $Placental parasitaemia 
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Table 4: Frequency of adverse events on day 3 after start of study treatment 
Adverse events ASAQ  (N=184) DHA-PPQ  (N=200) p-value 
    
Anorexia *[n(%)] 
 
41 (22.3) 24 (12.0) 0.007 
&Nausea 
 
5 (2.6) 0 (0.0) 0.02 
Vomiting 
 
54 (29.4) 39 (19.5) 0.02 
Abdominal pain 
 
53 (28.8) 48 (24.0) 0.29 
Diarrhoea 
 
21 (11.4) 26 (13.0) 0.64 
Dizziness 
 
49 (26.6) 29 (14.5) 0.003 
Sleeplessness 
 
31 (16.9) 21 (10.5) 0.07 
Nightmares 
 
30 (16.3) 20 (10.0) 0.07 
Visual disturbance 
 
10 (5.4) 10 (5.0) 0.85 
Tinnitus 
 
16 (8.7) 11 (5.5) 0.22 
General weakness 
 
115 (62.5) 77 (38.5) <0.0001 
Itching 
 
34 (18.5) 28 (14.0) 0.23 
*
Adverse events presented as no. reporting AE and percentage. Occurrences of AEs were not mutually exclusive 
as individuals mentioned more than one. &for nausea (ASAQ=194, DHA-PPQ=209). 
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Table 5: Frequency of adverse events on day 7 after start of study treatment 
 
Adverse events 
 
ASAQ  (N=182) DHA-PPQ  (N=187) p-value 
Anorexia *[n(%)] 
 
17 (9.3) 11 (5.9) 0.21 
Nausea 
 
0  0  
Vomiting 
 
24 (13.2) 15 (8.0) 0.11 
Abdominal pain 
 
37 (20.3) 35 (18.7) 0.70 
Diarrhoea 
 
11 (6.0) 11 (6.0) 0.96 
Dizziness 
 
25 (13.7) 15 (8.0) 0.08 
Sleeplessness 
 
36 (19.8) 21 (11.2) 0.02 
Nightmares 
 
20 (11.0) 8 (4.3) 0.02 
Visual disturbance 
 
3 (1.7) 0  0.08 
Tinnitus 
 
16 (8.8) 10 (5.4) 0.20 
General weakness 
 
67 (36.8) 48 (25.7) 0.02 
Itching 20 (11.0) 17 (9.1) 0.54 
* 
Adverse events presented as no. reporting AE and percentage. Occurrences of AEs were not mutually exclu-
sive as individuals mentioned more than one. 
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Fig 1: Trial Profile 
*1 each withdrawn for persistent vomiting after a repeat initial dose of DHA-PPQ, onset of pregnancy-induced hypertension (PIH) and occurrence of antepartum haemorrhage (placental 
abruption). **Withdrawn for protocol violation on the part of recruiters (it was realized this was a case of twin pregnancy). TS is treatment success and TF is treatment failure. PP is per 
protocol and MITT is modified intention to treat. Line arrows show participant flow and block arrows show numbers analysed 
 
 
212 allocated DHA-PPQ 205 allocated ASAQ 
2 withdrew consent, 3 
withdrawn* and 3 lost 
to follow-up 
  
4 withdrew consent, 8 lost to 
follow-up 
 
TS 200 
TF 4 
TS 186 
TF 7 
2 withdrew consent, 
1 lost to follow-up 
 
1 withdrawn**, 2 lost 
to follow-up 
 
TS 192 
TF 9 
TS 182 
TF 8 
2 lost to follow-up, 1 
missed visit at Day 28 
 
2 withdrew consent, 2 lost to 
follow-up, 2 missed visits at D28 
 
 
 
 
TS 191 
TF7 
TS 174 
TF 10 
8 lost to follow-up, 1 missed 
visit at Day 28 incorporated 
at Day 42 
 
6 lost to follow-up, 2 missed visits 
at Day 28 incorporated at Day 42 
 
TS 185 
TF 6 
 
 
 
 
TF 6 
 
 
TS 173 
TF 7 
        417    randomised 
 
3464 pregnant women assessed 
for eligibility.  
 
2876 RDT negative 
59 RDT positive but microscopy 
negative 
10 Twin gestation                
57 Gestation<15 weeks       
10 Lived outside area           
 35 refused consent             
 
190 and 198 women 
analysed in PP and MITT 
analyses respectively 
178 and 184 women analysed in the PP 
and MITT analyses respectively 
190 and 191 women analysed in PP 
and MITT analyses respectively 
rererrespectively 
178 and 180 women analysed in the 
PP and MITT analyses respectively 
